Good taking us. the you for to thank time morning, and join
strategic priorities spin-off of start where Let's Slide have our X, XXXX. with we April that see the executed three since you will in
base First, the we global category strengthen maintaining continue devices. our to leadership business injection position while of our insulin in
our proud being for as market, ourselves Second, type made we an activities form additional we stand-up well operationally developed invest significant have progress these and in is independent each M&A progress as program made within to finally, am X as we to goals. establish of and company. necessary separation that the partnership opportunities. seeking insulin for our notably most significant pass And have continue the I of around growth,
Turning to third some quarter highlights.
revenue currency our constant to During based $XXX.X When approximately of injection our with of results that and on core the execution the quarter, million We prior sales aligned our business financial basis. were currency expectations. parent, manufacturing former constant decrease and basis period. of X.X% for non-diabetes generate we X.X% the as-reported an led a a generated on to third normalizing our on a prior transient X.X% which products that to revenue declined represented compared revenue disciplined team's decrease year as contract by the of
rebalancing growing remained first quarter ERP constant was and our primarily currency something during and injection revenue to call basis, that had this basis, constant some year-to-date that months year-over-year we implementations earnings that a quarter our lower the was during occurred currency following basis. X.X% a the second expected While year. on has on X third fiscal stable, was due our occurred our inventory business the a on highlighted distributors with our of core of On
past eliminate what GLP-X of do independent, need our come might and on over not that delivery. have while people has news insulin several Based and much on the year, past with onset insulin they the the view diabetes GLP-X delay the have may they the insulin. out Over for becoming years, is regarding impact seen we
within years In use the needle, end, an requires to fact, be over and the as first eventually this will this of of administration. the pen to needs expect product benefit. therefore for growing countries to of an auto-injector the needles come we pen other To months identified stand with the and method help product in used new to administration. small that We to which intend a of expand people product we several the next continues We injector, to the a GLP-X GLP-X meet can needle offering market this have of from for number pen to will believe a introduce administration evolve that several pen we in that pens that future. Germany next using opportunity GLP-X pack
distribution activities. to in of Turning ERP network services progress shared significant of made the own to that we separation own system, operationalization I'm pleased and report our capabilities. our implementation
are XX% and in systems regions, of operational our cover our capabilities which base. revenue approximately Now
transition, a to activities Looking distribution remaining fiscal packaging ahead, all on from program of XXXX. these Once the year network by entails to implementations, are product exception with early the the complete separation ours. shared track complete, deferred BD's and brand implementations remain we be closing jurisdictions, which only ERP will few service changing brand separation
been for as they associated continue with accustomed important packaging. boxes people feel will years. same and or fiscal is schemes since experience We to have product with program needs execution we this color Notably, to the diabetes changing the the This spin-off XXXX. many this that not been year and are the our for to we look of phases intend transition our in begin planning have on during
to on [indiscernible] Regarding the progress we patent our open insulin platform. program, continue
submitted application. from XXXX. the application a this XXX(k) the FDA As questions a we year, of concerning December reminder, earlier in we that FDA received to And
data We have from feedback responded and the the with since await FDA. necessary
pump at will the appropriate patch the insulin updates the to We continue provide our community progress times. on to investment regarding
delivery abstracts the point sponsored and manage XX fewer Association insulin with that Relating through market, sessions diabetes longer Diabetes which patch pump American insulin larger of at over time. X to entering our a with patches disposable adults times could for objective the infusion reservoir, wear potential the XXX-unit to two to provide scientific we pump a better type
learned the the reaffirms diabetes with data with their The health a what people validates insulin speaking critical living presented care with from we've for that reservoir. among and population and is there thesis diabetes unmet our need pumps type larger X providers
our had another metrics year quarter the our we reaffirming financial So as ranges while key for results and fiscal the based remainder year-to-date tightening revenue to raising again range. our as of we of summarize, for are the well performance on good guidance expectations guidance and
our more Now let's performance third review revenue in quarter a and bit year-to-date detail.
$XXX.X basis that million, when represented As for QX, sell reported I the X.X% constant or a changes non-diabetes basis generated normalizing revenue we impact BD. revenue of we before, a contract in on to of mentioned a manufacture decrease and and of the X.X% on which year-over-year [indiscernible] currency of decrease of products during X.X% the
When lower normalizing U.S., ERP approximately implementation. during the quarter, The of year-over-year and due decline revenue approximately advanced $XXX.X was X.X% constant revenue inventory X.X%. distributors U.S. purchases levels basis. was primarily their U.S. currency revenue, the our contract decline a within manufacturing QX making was revenue constant Within totaled to within the the after currency our expected ahead underlying of a represented for million, on normalizing which year-over-year
price price our as volume increase well partially This offset adjustments. effect by went April decline As favorable gross to that X. into net annual was on and
Turning to our international business.
quarter X.X%. our decline the Like of expected customers equated primarily was totaled million, to constant During a the revenue to which QX, decline of the of currency year-over-year $XXX.X implementation. currency International timing revenue was this in ERP advance that in advanced due purchases and constant made within U.S.,
remarks. occurred me financial That injection more separation And to call the business our Jake? third all results that well XXXX, stable, updated in during through to quarter currency the remained you year year X.X% my core constant year-to-date with activities that, let completes as take through over basis. financial on guidance full as detail. fiscal turn Jay Importantly, growing a our prepared